Beiley Biofund, Inc.
TTPEX:788227.00
TWD
-0.20
(-0.74%)
ISIN
TW0007882003
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Full Time Employees
- 14
- Sector
- Finance
- Industry
- Investment managers
- Address
- Taiwan
- Website
- beileybiofund.com
- Similar Companies
- Business
- Beiley Biofund, Inc. is a venture capital and private equity investment firm specializing in direct equity investments, corporate incubation, and strategic growth capital for the life sciences, biotechnology, and healthcare sectors. Founded on October 15, 2013, and headquartered in Taipei, Taiwan, the company focuses on identifying and financing high-growth biotechnology enterprises addressing high unmet medical needs across oncology, immunology, ophthalmology, rare diseases, and age-related chronic illnesses. Beiley Biofund operates primarily within Taiwan and extends its investment reach across global life sciences hubs, particularly North America and the Asia-Pacific region, bridging domestic clinical and biomanufacturing capabilities with international biotech development. The company provides a comprehensive suite of financial, strategic, and advisory solutions to emerging biomedical enterprises, comprising early-stage venture financing; seed, Series A, and Series B capital rounds; late-stage growth equity; corporate incubation and entity structuring; technology commercialization and intellectual property valorization advisory; preclinical and clinical development guidance; cross-border regulatory strategy consulting; licensing and strategic alliance facilitation; merger and acquisition advisory; and capital market listing preparation. Beiley Biofund deploys capital across specialized biotechnology subsectors, including small molecule pharmaceuticals; biologic macromolecules and recombinant proteins; nucleic acid therapeutics and mRNA platforms; cell and gene therapies; regenerative medicines; clinical-stage in vitro diagnostics; advanced medical devices; and veterinary medicines. Beiley Biofund manages a diversified portfolio of innovative biotechnology companies, offering active post-investment management to maximize commercial value. Its portfolio engagement spans companies advancing novel therapeutic assets and medical platforms, such as Belite Bio, Inc., Lin Bioscience, Taiwan Bio Therapeutics, Ascendo Biotechnology, VerImmune, and ImmunAdd. The firm caters to biotechnology founders, academic spinoffs, clinical-stage drug developers, institutional investors, and sovereign investment partners seeking domain-specialized capital deployment. In recent corporate developments, the company underwent a major strategic transformation from its legacy operational model as Grand Fortune Venture Capital Co., Ltd., a captive venture vehicle within the Grand Fortune Securities Group, into an independent evergreen venture capital entity operating under the name Beiley Biofund, Inc. This strategic shift established a specialized, autonomous management team combining capital markets expertise with deep biomedical research capabilities. Following this restructuring, Beiley Biofund expanded its investment mandate to support global biotech unicorns and completed its public registration and listing on the Taipei Exchange Emerging Stock Board under ticker symbol 7882 in December 2025. The firm continues to broaden its cross-border strategic alliances, deploying capital into next-generation modalities and co-investing with international venture partners to accelerate global clinical pipelines.